Anterior cruciate ligament reconstruction with bone-patellar tendon-bone autograft versus allograft in young patients

Alfred W. Atanda
Alfred I duPont Hospital for Children

Daniel F. O'Brien
Thomas Jefferson University, daniel.o'brien@jefferson.edu

Matthew J. Kraeutler
Rothman Institute

Russell R. Flato
Rothman Institute

Matthew R. Salminen
Rothman Institute

*See next page for additional authors*

Let us know how access to this document benefits you

Follow this and additional works at: https://jdc.jefferson.edu/rothman_institute

Part of the Orthopedics Commons

Recommended Citation

https://jdc.jefferson.edu/rothman_institute/73
Anterior Cruciate Ligament Reconstruction with Bone-Patellar Tendon-Bone Autograft Versus Allograft in Young Patients

Alfred Atanda, MD1, Daniel Francis O’Brien, BA2, Matthew John Kraeutler, BS3, Russell R. Flato, BA3, Matthew Robert Salminen, BA/BS3, Kevin Henrichsen, BA2, Patrick Kane, MD4, Christopher C. Dodson, MD5, Steven B. Cohen, MD6, Michael G. Ciccotti, MD7

1Alfred I duPont Hospital for Children, Wilmington, DE, USA, 2Thomas Jefferson University, Philadelphia, PA, USA, 3Rothman Institute, Philadelphia, PA, USA, 4The Rothman Institute, Philadelphia, PA, USA, 5Rothman Institute of Orthopaedics, Philadelphia, PA, USA, 6Rothman Institute, Media, PA, USA, 7Rothman Institute @ Jefferson, Philadelphia, PA, USA.

Objectives: Traditionally, bone-patellar tendon-bone (BTB) autograft has been the gold standard graft choice for younger, athletic patients requiring ACL reconstruction. However, donor site morbidity, post-operative patella fracture, and increased operative time have led many surgeons to choose BTB allograft for their reconstructions. Opponents of allografts feel that slower healing time, higher rate of graft failure, and potential for disease transmission makes them undesirable graft choices in athletic patients. The purpose of this study is to evaluate the clinical outcomes, both subjective and objective, of young patients that who have undergone either BTB autograft or allograft reconstructions with a minimum of 2-year follow-up.

Methods: One hundred and twenty patients (60 autograft, 60 allograft), age 25 and below at time of surgery, were contacted after being retrospectively identified as patients having an ACL reconstruction with either a BTB allograft or autograft by one senior surgeon. Patients were administered the Lysholm Knee Scoring Scale and IKDC Subjective Knee Evaluation questionnaires. Fifty (25 BTB autograft and 25 BTB allograft) of the 120 returned for physical examination as well as completion of a single leg hop test and laxity evaluation using a KT-1000 arthrometer evaluation. Of the 120 patients contacted, there were a total of 7 failures (5.8%) requiring revision, 6 in the allograft group (86%) and 1 in the autograft group (14%).

Results: The average Lysholm scores were 89.0 and 89.56 and the average IKDC scores were 90.8 and 92.1 in the autograft and allograft groups respectively. The differences in the Lysholm scores and the IKDC scores were not significant. The single leg hop and KT-1000 scores were also not significantly different. One autograft patient had a minor motion deficit. Three allograft patients had a grade 1 Lachman and pivot glide. One autograft patient and two allograft patients had mild patellafemoral crepitus. There was no significant difference in anterior knee pain between the two groups.

Conclusion: There is no significant difference in patient-rated outcome between ACL reconstructions using BTB autografts versus allografts. However, the overall study group did reveal an increased failure rate requiring revision in the allograft group.

The Orthopaedic Journal of Sports Medicine, 3(3)(suppl 1)
DOI: 10.1177/2325967115S00016
©The Author(s) 2015